Royal Bank of Canada’s Abeona Therapeutics ABEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $29K | Buy |
6,500
+2,155
| +50% | +$10.8K | ﹤0.01% | 5735 |
|
|
2025
Q4 | $22K | Buy |
4,345
+1,767
| +69% | +$8.89K | ﹤0.01% | 5973 |
|
|
2025
Q3 | $14K | Sell |
2,578
-4,508
| -64% | -$28.6K | ﹤0.01% | 6356 |
|
|
2025
Q2 | $40K | Buy |
7,086
+5,132
| +263% | +$29.2K | ﹤0.01% | 6006 |
|
|
2025
Q1 | $9K | Buy |
+1,954
| New | +$10.6K | ﹤0.01% | 6178 |
|
|
2024
Q3 | – | Sell |
-214
| Closed | -$1K | – | 6780 |
|
|
2024
Q2 | $1K | Sell |
214
-586
| -73% | -$2.99K | ﹤0.01% | 6776 |
|
|
2024
Q1 | $6K | Sell |
800
-209
| -21% | -$1.32K | ﹤0.01% | 6367 |
|
|
2023
Q4 | $5K | Buy |
1,009
+1,002
| +14,314% | +$4.41K | ﹤0.01% | 6640 |
|
|
2023
Q3 | $0 | Buy |
+7
| New | +$26 | ﹤0.01% | 7015 |
|
|
2022
Q1 | – | Sell |
-271
| Closed | -$2K | – | 7695 |
|
|
2021
Q4 | $2K | Buy |
271
+268
| +8,933% | +$4.92K | ﹤0.01% | 7384 |
|
|
2021
Q3 | $0 | Sell |
3
-139
| -98% | -$4.45K | ﹤0.01% | 7589 |
|
|
2021
Q2 | $6K | Sell |
142
-140
| -50% | -$5.71K | ﹤0.01% | 7012 |
|
|
2021
Q1 | $13K | Sell |
282
-142
| -33% | -$7.82K | ﹤0.01% | 6667 |
|
|
2020
Q4 | $17K | Buy |
424
+339
| +399% | +$11.5K | ﹤0.01% | 6125 |
|
|
2020
Q3 | $2K | Sell |
85
-83
| -49% | -$5.23K | ﹤0.01% | 6289 |
|
|
2020
Q2 | $12K | Sell |
168
-9
| -5% | -$622 | ﹤0.01% | 5761 |
|
|
2020
Q1 | $9K | Sell |
177
-216
| -55% | -$14.4K | ﹤0.01% | 5848 |
|
|
2019
Q4 | $32K | Buy |
393
+220
| +127% | +$15.5K | ﹤0.01% | 5654 |
|
|
2019
Q3 | $10K | Sell |
173
-94
| -35% | -$7.04K | ﹤0.01% | 5771 |
|
|
2019
Q2 | $32K | Sell |
267
-17
| -6% | -$2.85K | ﹤0.01% | 5480 |
|
|
2019
Q1 | $52K | Sell |
284
-41
| -13% | -$7.33K | ﹤0.01% | 5131 |
|
|
2018
Q4 | $58K | Sell |
325
-147
| -31% | -$32.1K | ﹤0.01% | 5013 |
|
|
2018
Q3 | $151K | Buy |
472
+20
| +4% | +$7.09K | ﹤0.01% | 4631 |
|
|
2018
Q2 | $181K | Buy |
452
+63
| +16% | +$27.5K | ﹤0.01% | 4462 |
|
|
2018
Q1 | $140K | Buy |
389
+72
| +23% | +$26.8K | ﹤0.01% | 4503 |
|
|
2017
Q4 | $126K | Buy |
317
+38
| +14% | +$15.7K | ﹤0.01% | 4685 |
|
|
2017
Q3 | $119K | Buy |
279
+239
| +598% | +$64.2K | ﹤0.01% | 4881 |
|
|
2017
Q2 | $6K | Hold |
40
| – | – | ﹤0.01% | 5968 |
|
|
2017
Q1 | $5K | Buy |
+40
| New | +$5.16K | ﹤0.01% | 6199 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6306 |
|
|
2015
Q4 | – | Sell |
-21
| Closed | -$2.11K | – | 6604 |
|
|
2015
Q3 | $2K | Sell |
21
-7
| -25% | -$929 | ﹤0.01% | 6365 |
|
|
2015
Q2 | $4K | Buy |
+28
| New | +$4.21K | ﹤0.01% | 6270 |
|
Other funds holding ABEO
NCM
ACM
CCC
SCM
VCM
PBM
KCM
Royal Bank of Canada's ABEO Position: Q1 2026 in Review
Royal Bank of Canada increased its Abeona Therapeutics (ABEO) stake by 50% in Q1 2026, buying an estimated $10.8K and bringing the position to 6,500 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #5735.
Royal Bank of Canada first reported a position in ABEO in Q2 2015 and has held it in 31 quarters since. The position peaked at $181K in Q2 2018. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.
- Royal Bank of Canada held 6,500 shares of Abeona Therapeutics worth $29K as of Q1 2026.
- Royal Bank of Canada bought 2,155 Abeona Therapeutics shares in Q1 2026, an estimated $10.8K.
- Abeona Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5735 holding.
- Royal Bank of Canada first reported a position in Abeona Therapeutics in Q2 2015 and has held it in 31 quarters since.
- Royal Bank of Canada's Abeona Therapeutics position peaked at $181K in Q2 2018.
- 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.